期刊
LARYNGOSCOPE
卷 122, 期 1, 页码 174-189出版社
WILEY
DOI: 10.1002/lary.22392
关键词
Neurofibromatosis type 2; merlin; vestibular schwannoma; AKT; histone deacetylase; histone deacetylase inhibitors; AR42; cell cycle arrest; apoptosis
资金
- National Institute of Deafness and Other Communication Disorders [K08 DC009644-01A1, R01 DC005985, 3R01DC005985-05S11]
- American Hearing Research Foundation [GRT00014844]
- Children's Tumor Foundation [DDI 2007-05-2]
- Triological Society [GRT00011359]
Objectives/Hypothesis: Recent studies indicate that vestibular schwannomas (VSs) rely on phosphatidylinositol 3-kinase/AKT activation to promote cell proliferation and survival; therefore, targeting AKT may provide new therapeutic options. We have previously shown that AR42, a novel histone deacetylase inhibitor, potently suppresses VS growth in vitro at doses correlating with AKT inactivation. The objectives of the current study were translational: 1) to examine the end biologic effects of AR42 on tumor growth in vivo, 2) to validate AKT as its in vivo molecular target, 3) to determine whether AR42 penetrates the blood-brain barrier (BBB), and 4) to study the pharmacotoxicity profile of AR42.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据